While the reduction in price target from $39 to $28 by Chardan Capital could be seen as a negative adjustment, the maintenance of a Buy rating suggests a continued positive outlook on the company's fundamentals. This mixed signal could lead to a neutral short-term impact on EyePoint Pharmaceuticals' stock price, as the market digests both the lowered price target and the reaffirmed confidence in the stock's potential.